COSCIENS Biopharma Inc. develops and commercializes products in the cosmeceutical, nutraceutical, and pharmaceutical sectors. The company shows strengths in liquidity with a current ratio of 4.33 and a solid gross margin of 55.3%. However, it faces concerns with a negative net margin of -6.4% and low returns on equity and assets. Despite high margins, the market cap of $8.60M suggests potential undervaluation, indicating a need for improved profitability to attract investors.
Loading financial metrics...
Revenue decreased 12.3% year-over-year from $9.4M to $8.3M.
Operating margin expanded by 92.0pp, demonstrating strong operational leverage.
Fortress balance sheet: cash covers total debt 2.7×, providing significant financial flexibility.
Excellent liquidity with current ratio of 4.3x ensures operational stability.
Low debt-to-revenue ratio of 23.6% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2026-Q2 (June 30, 2026)